HIV Pol Recombinant DNA Constructs for Safe Diagnostic Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The development of effective diagnostic and therapeutic tools for HIV infection is hindered by the lack of available HIV nucleotide sequences for recombinant protein production, concerns over the infectivity of tissue-cultured viral polypeptides, and uncertainties regarding the antigenic similarity of recombinant and native HIV proteins.

Innovation Solution

Nucleotide sequences specific to HIV are provided for detecting the virus and producing recombinant polypeptides, including DNA constructs and methods for cloning, expression, and detection of HIV, ensuring immunological non-cross-reactivity with HTLV-I and HTLV-II, and the production of vaccines and diagnostic tools.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If HIV is propagated in human mitogen-activated T cells to produce viral polypeptides, then sufficient quantities of virus can be produced for serology assays, but the risk of infectivity from live intact virus increases

Engineering Contradiction:

Improvequantity of virusVSAvoidinfectivity risk

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and isolates specific HIV nucleotide sequences (gag, pol, env genes) from the complete viral genome, then uses these extracted genetic elements to produce recombinant polypeptides through expression in host cells. This extraction approach allows production of viral proteins without propagating complete infectious virus particles, thereby maintaining quantity while reducing infectivity risk

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent creates recombinant copies of HIV polypeptides by inserting cloned viral gene sequences into expression vectors and producing them in host cells. These recombinant copies serve as safe alternatives to native viral proteins, providing the necessary quantity for diagnostic assays without the hazards associated with live virus propagation

Inventive Principle:

Principle #26Copying

2Reliability

If recombinant HIV polypeptides are produced using available nucleotide sequences, then safe diagnostic tools can be developed, but uncertainties remain regarding antigenic similarity to native HIV proteins

Engineering Contradiction:

Improvesafety of diagnostic toolsVSAvoiduncertainty in antigenic similarity

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent employs immunoblotting assays where sera from HIV-infected individuals are tested against recombinant polypeptides to verify antigenic recognition. This feedback mechanism confirms that the recombinant proteins maintain sufficient antigenic similarity to native HIV proteins, validating their use in diagnostic applications while ensuring safety

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent uses transient expression systems in host cells to produce recombinant HIV polypeptides for diagnostic purposes. These short-lived recombinant protein products serve as disposable diagnostic reagents that provide safe, sufficient quantities without requiring long-term maintenance of infectious virus stocks

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Productivity

If HIV nucleotide sequences are used for recombinant protein production, then large quantities of polypeptides can be produced, but concerns over infectivity of tissue-cultured viral polypeptides persist

Engineering Contradiction:

Improveproduction quantity of polypeptidesVSAvoidinfectivity concern

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the HIV genome into distinct functional genes (gag, pol, env) and produces each as separate recombinant polypeptides or fusion proteins. This segmentation allows high-productivity recombinant expression of individual viral proteins without the need to propagate complete infectious virus, thereby achieving high production quantities while eliminating infectivity concerns

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses recombinant DNA technology as an intermediary system, where cloned viral gene sequences serve as mediators between the original viral genome and the final diagnostic products. This intermediary approach enables high-yield production of viral polypeptides through expression vectors without requiring tissue culture of live virus, thus achieving productivity while avoiding infectivity

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS7527925B1Purified pol DNA, a recombinant DNA construct for expression of HIV pol polypeptide sequences and a cell containing such construct

Publication Date: 2009.05.05 GRIFOLS WORLDWIDE OPERATIONS

AI summary

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.